Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals
Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
ENY
0.00%
$13.34
AII S&P/ASX 200 ENERGY - Corporate Spotlight
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.